Gilead Sciences, Inc.
Explore Gilead Sciences, Inc.
Core profile pages, annual revenue records, and related research hubs for this company.
CorpDigest
Gilead Sciences, Inc.
Explore Gilead Sciences, Inc.
Core profile pages, annual revenue records, and related research hubs for this company.
Annual Revenue
FY2023 Revenue
$27.1B
▼ 1.5% vs FY2022 ($27.5B)
Source: Annual report / company filing
Gilead Sciences, Inc. reported $27.1B in revenue for fiscal year 2023. This represents a decline of 1.5% compared to the 2022 figure of $27.5B. In 2024, revenue increased to $28.5B.
Reported sales slipped 1.5% versus 2022 as the COVID antiviral Veklury retreated from its $5.5 billion 2022 peak, outweighing continued growth across the core HIV franchise.
| Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $29.4B | — | +3.3% |
| FY2024 | $28.5B | $6.6B | +5.2% |
| FY2023 | $27.1B | — | -1.5% |
| FY2022 | $27.5B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.